Loading...
•
Sep 30, 2020
ANI Pharmaceuticals Q3 2020 Earnings Report
ANI Pharmaceuticals reported third quarter results with net revenues of $53.0 million and net income of $0.4 million.
Key Takeaways
ANI Pharmaceuticals reported third quarter 2020 results with net revenues of $53.0 million, a net income of $0.4 million, and diluted EPS of $0.04. The company is on track with the Cortrophin® Gel sNDA re-filing and has a commercialization and operational launch readiness plan underway. A new CEO and Board members have been added to drive business growth.
Third quarter net revenues were $53.0 million.
Net income for the third quarter was $0.4 million, with diluted EPS of $0.04.
Adjusted non-GAAP diluted EPS was $0.97 for the third quarter.
Cortrophin Gel sNDA re-filing is on track with commercialization plans underway.
Revenue by Segment
Forward Guidance
The company anticipates that Cortrophin-related expenses in the fourth quarter of 2020 will be moderately higher than those of the third quarter, as they continue to focus on their sNDA resubmission efforts.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...